When there is no mutation in either the KIT or PDGFRA gene, the GIST should be subjected to targeted gene panel analysis or whole-exome sequencing; then, the patient can be advised to receive potential therapeutic agents based on the results (Figure 1 and Table 1). Here, PDGFRA is linked to gastrointestinal stromal tumor.